Home » Stocks » Fulcrum Therapeutics

Fulcrum Therapeutics, Inc. (FULC)

Stock Price: $18.25 USD 0.40 (2.24%)
Updated Jul 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 500.50M
Revenue (ttm) 750,000
Net Income (ttm) -64.29M
Shares Out 27.40M
EPS (ttm) -14.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 6, 2020
Last Price $18.25
Previous Close $17.85
Change ($) 0.40
Change (%) 2.24%
Day's Open 18.11
Day's Range 17.15 - 18.39
Day's Volume 49,748
52-Week Range 4.37 - 22.96

More Stats

Market Cap 500.50M
Enterprise Value 418.20M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 27.40M
Float 11.61M
EPS (basic) -8.79
EPS (diluted) -14.92
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 553,712
Short Ratio 8.49
Short % of Float 3.04%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 667.34
PB Ratio 7.96
Revenue 750,000
Operating Income -65.79M
Net Income -64.29M
Free Cash Flow n/a
Net Cash 82.30M
Net Cash / Share 3.00
Gross Margin n/a
Operating Margin -8,771.47%
Profit Margin -9,116.40%
FCF Margin n/a
ROA -48.25%
ROE -94.48%
ROIC -383.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$26.40*
(44.66% upside)
Low
23.0
Current: 18.25
High
29.0
Target: 26.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-84.22-33.50-22.99
Net Income-82.68-32.59-22.96
Shares Outstanding11.051.260.71
Earnings Per Share-8.13-31.14-35.68
Operating Cash Flow-39.48-22.56-20.07
Capital Expenditures-0.85-8.98-1.91
Free Cash Flow-40.34-31.54-21.98
Cash & Equivalents97.8173.890.41
Net Cash / Debt97.8173.890.41
Assets11085.774.34
Liabilities23.299.773.02
Book Value87.15-63.67-33.27
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Fulcrum Therapeutics, Inc.
Country United States
Employees 73
CEO Robert J. Gould

Stock Information

Ticker Symbol FULC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FULC

Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. It has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.